Trial Profile
Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine; Metronidazole
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms APPRECIA
- 16 Mar 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 13 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 18 Nov 2013 Planned end date changed from 1 Jan 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.